$CDXS News
Last published 1d ago
- 1d agoCDXSTRINCodexis Enters into $60 Million Term Loan Facility with Trinity CapitalGlobeNewswireREDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into
- 1d agoCDXSTRINCodexis Enters into $60 Million Term Loan Facility with Trinity CapitalGlobeNewswireInitial drawdown of $42.5 million to refinance existing term loan
- 2d agoCDXSCodexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing CapabilitiesGlobeNewswireREDWOOD CITY, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS) a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, presented
- 2d agoCDXSCodexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing CapabilitiesGlobeNewswireData shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform...
- 1w agoCDXSCodexis to Report Third Quarter 2026 Financial Results on November 12GlobeNewswireREDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it
- 2mo agoCDXSCodexis to Participate in Cantor Global Healthcare Conference 2026GlobeNewswireREDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the
- 3mo agoCDXSCodexis Reports Second Quarter 2026 Financial Results - CODEXIS INCEarnings Call TranscriptsGreetings and welcome to the Codex's second quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow a formal presentation. If an
- 3mo agoCDXSCodexis Appoints David Butler, PhD, to Strategic Advisory BoardGlobeNewswireREDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today
- 3mo agoCDXSCodexis to Report Second Quarter 2026 Financial Results on August 11GlobeNewswireREDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it
- 3mo agoCDXSCodexis Announces Pricing of Public Offering of Common StockGlobeNewswireREDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today
- 3mo agoCDXSCodexis Announces Proposed Public Offering of Common StockGlobeNewswireREDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today
- 5mo agoCDXSCodexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USAGlobeNewswireREDWOOD CITY, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA
- 6mo agoCDXSCodexis Reports 2026 Q1 Earnings Call - CodexisEarnings Call TranscriptsGreetings and welcome to the Codexist Report 2026 Q1 Earnings Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should requ
- 6mo agoCDXSCodexis Reports First Quarter 2026 Financial ResultsGlobeNewswireReports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing
- 6mo agoCDXSCodexis to share RNA manufacturing advances at TIDES USAGlobeNewswireREDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO
- 6mo agoCDXSCodexis to Report First Quarter 2026 Financial Results on May 7GlobeNewswireREDWOOD CITY, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it
- 8mo agoCDXSCodexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing PlatformPR NewswireCodexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has ...
- 8mo agoCDXSCodexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11GlobeNewswireREDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it
- 8mo agoCDXSCodexis to Participate in TD Cowen 46th Annual Health Care ConferenceGlobeNewswireREDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the
- 9mo agoCDXSCodexis Achieves ISO 9001:2015 CertificationGlobeNewswireREDWOOD CITY, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Codexis Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today that it has earned
- 10mo agoCDXSCodexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide TherapeuticsPR NewswireCodexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of...
- 1y agoCDXSCodexis Announces Signing of Lease for GMP Manufacturing FacilityGlobeNewswireREDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that
- 1y agoCDXSCodexis Reports Third Quarter 2025 Financial ResultsGlobeNewswireAnnounces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov. 06, 2025
- 1y agoCDXSCodexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA ManufacturingPR NewswireCodexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko...
- 1y agoCDXSCodexis to Report Third Quarter 2025 Financial Results on November 6GlobeNewswireREDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that
- 1y agoCDXSCodexis to Participate in Cantor Global Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced the
- 1y agoCDXSCodexis, Inc. (CDXS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCDXSCodexis Reports Second Quarter 2025 Financial ResultsGlobeNewswireAnnounces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $27.3M raised
- 1y agoCDXSCodexis to Report Second Quarter 2025 Financial Results on August 13GlobeNewswireREDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that
- 1y agoCDXSCodexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNAGlobeNewswirePresentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases Management to host conference call today at 8 am Eastern
- 1y agoCDXSCodexis to Participate in Jefferies Global Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will
- 1y agoCDXSCodexis Reports First Quarter 2025 Financial ResultsGlobeNewswireSecured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES
- 1y agoCDXSCodexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual MeetingGlobeNewswireCodexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases
- 1y agoCDXSCodexis to Report First Quarter 2025 Financial Results on May 14GlobeNewswireREDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report
- 1y agoCDXSCodexis Announces Byron Dorgan to Retire from Board of DirectorsGlobeNewswireREDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that Byron Dorgan
- 1y agoCDXSCodexis Appoints Cynthia Collins to Board of DirectorsGlobeNewswireREDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of
- 1y agoCDXSCodexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing ServicesGlobeNewswireRepresents first project to enter the ECO Synthesis™ Innovation Lab Core enzymes for ECO Synthesis™ technology have transitioned from research into development and scale-up as the first step in securing
- 1y agoCDXSCodexis Announces New Employment Inducement GrantsGlobeNewswireREDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of
- 1y agoCDXSCodexis Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsGlobeNewswireTotal revenue of $59.3 million for the fiscal year ended December 31, 2024 Expect double digit growth for total revenue in 2025 2025 to demonstrate acceleration of commercial growth through double-stranded RNA
- 1y agoCDXSCodexis to Participate in TD Cowen 45th Annual Health Care ConferenceGlobeNewswireREDWOOD CITY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will
- 1y agoCDXSCodexis Announces New Employment Inducement GrantsGlobeNewswireREDWOOD CITY, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of
- 1y agoCDXSCodexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27thGlobeNewswireREDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report
- 1y agoCDXSCodexis Appoints Arthur Levin, PhD, to Strategic Advisory BoardGlobeNewswireREDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of
- 1y agoCDXSCodexis Appoints Christos Richards to Board of DirectorsGlobeNewswireREDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of
- 1y agoCDXSCodexis Announces New Employment Inducement GrantsGlobeNewswireREDWOOD CITY, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of
- 1y agoCDXSCodexis Announces New Employment Inducement GrantsGlobeNewswireREDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of
- 1y agoCDXSCodexis to Participate in Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswireREDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will
- 1y agoCDXSCodexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi TherapeuticsGlobeNewswire—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type
- 1y agoCDXSCodexis Announces Appointment of Raymond De Vré, PhD, to Board of DirectorsGlobeNewswireREDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of
- 2y agoCDXSCodexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi TherapeuticsGlobeNewswire—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes—